DAWNRAYS PHARMA2348.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, DAWNRAYS PHARMA (2348.HK) trades at a P/E of 5.32x, P/B of 0.36x, P/S of 1.08x, and a dividend yield of 6.70%.
Longitudinal percentile comparison: P/E sits at the 36th percentile over the trailing 10Y window (vs. 55th percentile over 3Y); P/B sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/S sits at the 1st percentile over the trailing 10Y window (vs. 1st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 5th percentile within its industry and the 20th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 6.74%, ranking at the 66th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 35.4 points — relying on either metric alone could be misleading. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. DAWNRAYS PHARMA operates in the Pharmaceutical Chemistry sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2348 · SEHK: 2348 · 2348
Want the full picture on whether DAWNRAYS PHARMA (2348.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 5.32 | ||||||
| P/B (MRQ) | 0.36 | ||||||
| P/S (TTM) | 1.08 | ||||||
| Dividend Yield | 6.70% | ||||||
| Buyback + Div Yield | 6.74% |